Healthcare Industry News: Breast Cancer Profile
News Release - December 6, 2011
Agendia Introduces the SYMPHONY(TM) Breast Cancer Profile With Paraffin Embedded TissueIRVINE, Calif. and AMSTERDAM , Dec. 6, 2011 -- (Healthcare Sales & Marketing Network) -- Agendia, an innovative molecular diagnostics company, today announced the introduction of formalin fixed, paraffin embedded tissue technology applied to their Symphony™ suite of breast cancer assays. Delivering Agendia's tests in a paraffin embedded tissue format offers their customers added convenience along with the superior science, development and validation found in Agendia's breast cancer Symphony suite.
Agendia's breast cancer Symphony suite of products leverage the predictive and prognostic power of four separate and distinct assays to provide a comprehensive decision support system. Symphony assists physicians in determining which patients will benefit from chemo therapy, hormonal therapy, or combination therapies, preventing unnecessary suffering from short and long term side effects and burdensome costs to the overall health care system. Symphony includes MammaPrint®, which determines the risk of recurrence; BluePrint™ determines molecular subtypes; TargetPrint® determines ER, PR and HER2 status; and TheraPrint® identifies alternative types of therapy for metastatic disease.
MammaPrint was the first in vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire clearance from the US Food and Drug Administration (FDA). Originally offered for fresh tissue specimens, MammaPrint accurately identifies the risk of disease recurrence for patients with early stage breast cancer.
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, BluePrint, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay, and TheraPrint, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of breast cancer tests, Agendia has a rich pipeline of genomic products in development based on its world-class quantitative gene expression platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2, MINDACT as well as other trials.
Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California , United States , and Amsterdam, the Netherlands . For more information, please visit www.agendia.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.